Special report: companion diagnostics--example of BRAF gene mutation testing to select patients with melanoma for treatment with BRAF kinase inhibitors.

©2011 Blue Cross and Blue Shield Association. Reproduction without prior authorization is prohibited. 1 NOTICE OF PURPOSE: TEC Assessments are scientific opinions, provided solely for informational purposes. TEC Assessments should not be construed to suggest that the Blue Cross Blue Shield Association, Kaiser Permanente Medical Care Program or the TEC Program recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service; any particular course of treatment, procedure, or service; or the payment or non-payment of the technology or technologies evaluated. Special Report: Companion Diagnostics—Example of BRAF Gene Mutation Testing to Select Patients with Melanoma for Treatment with BRAF Kinase Inhibitors